US equities
|
SPCX
$168.82
▲+6.20%
NVDA
$237.49
▲+1.51%
MU
$1,065.24
▼-0.90%
TSLA
$380.86
▲+2.77%
MSFT
$524.77
▲+1.40%
SNDK
$1,714.33
▼-0.33%
INTC
$116.88
▼-2.06%
META
$744.45
▲+2.25%
SPCX
$168.82
▲+6.20%
NVDA
$237.49
▲+1.51%
MU
$1,065.24
▼-0.90%
TSLA
$380.86
▲+2.77%
MSFT
$524.77
▲+1.40%
SNDK
$1,714.33
▼-0.33%
INTC
$116.88
▼-2.06%
META
$744.45
▲+2.25%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Verve Therapeutics, Inc. - Common Stock
(NQ:
VERV
)
11.13
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verve Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
November 06, 2025
A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as...
Via
TokenRing AI
Topics
Artificial Intelligence
Climate Change
Intellectual Property
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
October 02, 2025
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented...
Via
TokenRing AI
Topics
Artificial Intelligence
Verve Therapeutics Inc (NASDAQ:VERV): A High-Growth Momentum Stock Aligned with Minervini’s Trend Model
↗
August 02, 2025
Verve Therapeutics (VERV) aligns with Minervini’s trend model, showing strong technicals, 93% 3-month growth, and 479% revenue surge—ideal for high-growth investors.
Via
Chartmill
3 Bullish Biotech Stocks With Explosive Growth Trends
↗
July 21, 2025
These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies
Via
MarketBeat
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
↗
July 15, 2025
Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.
Via
MarketBeat
Topics
Economy
Stocks
VERVE THERAPEUTICS INC (NASDAQ:VERV) - A High-Growth Biotech Stock Meeting Minervini's Criteria
↗
July 09, 2025
VERVE THERAPEUTICS (VERV) is a high-growth biotech stock meeting Minervini's Trend Template criteria, with strong revenue growth, bullish technicals, and upward earnings revisions.
Via
Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
June 27, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
↗
June 20, 2025
Via
The Motley Fool
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLP, VERV, CVAC on Behalf of Shareholders
June 20, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV
June 18, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
↗
June 18, 2025
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.
Via
Benzinga
This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
↗
June 18, 2025
Via
Benzinga
Market Monitor News June 18 (Jabil, Reddit & Verve Therapeutics UP - Solar Stocks First Solar, Sunrun & SolarEdge DOWN)
↗
June 18, 2025
Wall Street stays cool despite geopolitical tension, weak retail data, and a meltdown in solar stocks.
Via
Chartmill
5 Analysts Assess Verve Therapeutics: What You Need To Know
↗
June 17, 2025
Via
Benzinga
These stocks are moving in today's session
↗
June 17, 2025
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of Shareholders
June 17, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
June 17, 2025
Via
Benzinga
Which stocks are moving on Tuesday?
↗
June 17, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via
Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
June 17, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders
June 17, 2025
From
Halper Sadeh LLC
Via
Business Wire
Why Verve Therapeutics Stock Is Skyrocketing Today
↗
June 17, 2025
Via
The Motley Fool
Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday
↗
June 17, 2025
Via
Benzinga
Which stocks are gapping on Tuesday?
↗
June 17, 2025
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via
Chartmill
Power Metallic (TSX.V: PNPN) Secures Largest Saudi License Amid June 2025 Gold Surge – Material Gains & More Stocks Inside
June 17, 2025
Via
AB Newswire
Verve Therapeutics Stock Rockets 75% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B: Retail Says Offer Is ‘Low’
↗
June 17, 2025
Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share,...
Via
Stocktwits
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
↗
June 17, 2025
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.
Via
Investor's Business Daily
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
↗
June 17, 2025
Via
Benzinga
Get insights into the top gainers and losers of Tuesday's pre-market session.
↗
June 17, 2025
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via
Chartmill
Shareholder Alert: The Ademi Firm Investigates Whether Verve Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
June 17, 2025
From
Ademi & Fruchter LLP
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
June 17, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
